Forte Biosciences
FBRX
26 hedge funds and large institutions have $97.1M invested in Forte Biosciences in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.
2,257% more capital invested
Capital invested by funds: $4.12M → $97.1M (+$93M)
242.41% more ownership
Funds ownership: 50.45% → 292.87% (+242%)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
8% more funds holding
Funds holding: 24 → 26 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$12.5M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.25M |
| 3 |
O
OrbiMed
New York
|
+$7.14M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5.65M |
| 5 |
TCM
Tybourne Capital Management
Hong Kong
|
+$5.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$445K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$394K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$73.3K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$33.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RFG
26
REAP Financial Group
Austin,
Texas
| $68 | – | – | – |
|
|
BCM
27
BML Capital Management
Zionsville,
Indiana
| – | -$394K | -70,468 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$73.3K | -13,096 | Closed |
|
|
ACM
29
ADAR1 Capital Management
Austin,
Texas
| – | -$33.5K | -6,000 | Closed |
|
|
30
UBS Group
Zurich,
Switzerland
| – | -$8.98K | -1,606 | Closed |
|
31
Osaic Holdings
Scottsdale,
Arizona
| – | -$112 | -20 | Closed |
|
32
Russell Investments Group
London,
United Kingdom
| – | -$100 | -18 | Closed |
|
33
Barclays
London,
United Kingdom
| – | -$6 | -1 | Closed |
|
FBRX Hedge Fund Activity: Q4 2024 in Review
26 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2024, worth a combined $97.1M — up 2,257% from $4.12M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FBRX positions and 7 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Fred Alger Management, adding an estimated $12.5M. The largest seller was Farallon Capital Management, cutting an estimated $445K.
- 26 institutional investors held Forte Biosciences (FBRX) as of Q4 2024, up from 24 in Q3 2024.
- Funds reported $97.1M of Forte Biosciences stock for Q4 2024, up 2,257% quarter-over-quarter.
- 9 funds opened new Forte Biosciences positions in Q4 2024 and 7 closed out, a net change of +2 holders.
- The largest Forte Biosciences buyer in Q4 2024 was Fred Alger Management, an estimated $12.5M added.
- The largest Forte Biosciences seller in Q4 2024 was Farallon Capital Management, an estimated $445K sold.
Based on aggregated 13F filings for Q4 2024.